
Smoking Cessation- Pipeline Insight, 2024
Description
Smoking Cessation- Pipeline Insight, 2024
DelveInsight’s, “Smoking Cessation- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Smoking Cessation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Smoking Cessation: Overview
Smoking cessation refers to the process of quitting smoking, a significant health decision that can drastically improve overall well-being and reduce the risk of numerous diseases, including cardiovascular diseases, chronic obstructive pulmonary disease (COPD), and lung cancer. Despite the addictive nature of nicotine, many individuals attempt to quit due to growing awareness of the associated health risks. Governments and health organizations globally promote smoking cessation through public health campaigns, providing resources such as quitlines, counseling, and pharmacological aids to increase the chances of success.
Quitting smoking often triggers withdrawal symptoms, which can be both physical and psychological. Common signs include intense cravings for nicotine, irritability, anxiety, difficulty concentrating, and restlessness. Physical symptoms may include headaches, increased appetite, weight gain, and digestive discomfort. These symptoms tend to peak within the first few days after quitting and gradually diminish over time, usually subsiding within a few weeks. However, the psychological dependence on nicotine may last longer, making relapse a common challenge.
Nicotine, a highly addictive substance found in tobacco, is the primary cause of smoking addiction. Once nicotine enters the bloodstream, it stimulates the release of dopamine, a neurotransmitter associated with pleasure and reward, which reinforces the habit of smoking. Over time, the body builds a tolerance to nicotine, leading to increased consumption to achieve the same effects. Diagnosis of nicotine dependence is often based on self-reported symptoms, including the inability to cut down on smoking, cravings, and withdrawal symptoms. Healthcare providers may use tools such as the Fagerström Test for Nicotine Dependence to assess the severity of addiction.
Several evidence-based treatments are available to support individuals in quitting smoking. Behavioral interventions such as counseling, cognitive-behavioral therapy (CBT), and support groups are commonly used to address the psychological aspects of addiction. Pharmacological treatments, including nicotine replacement therapy (NRT), varenicline (Chantix), and bupropion (Zyban), can help reduce cravings and withdrawal symptoms. Combining both behavioral and pharmacological approaches tends to be the most effective strategy for long-term cessation. Additionally, mobile apps, quitline services, and digital programs offer accessible support for those seeking to quit smoking.
""Smoking Cessation- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Smoking Cessation pipeline landscape is provided which includes the disease overview and Smoking Cessation treatment guidelines. The assessment part of the report embraces, in depth Smoking Cessation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Smoking Cessation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation R&D. The therapies under development are focused on novel approaches to treat/improve Smoking Cessation.
This segment of the Smoking Cessation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Smoking Cessation Emerging Drugs
- Cytisinicline: Achieve Life Sciences
- EMB-001: Embera Pharmaceuticals
- SBP-9330: Camino Pharma, LLC
Further product details are provided in the report……..
Smoking Cessation: Therapeutic Assessment
This segment of the report provides insights about the different Smoking Cessation drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Smoking Cessation
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Smoking Cessation: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Smoking Cessation therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Smoking Cessation drugs.
Smoking Cessation Report Insights
- Smoking Cessation Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Smoking Cessation drugs?
- How many Smoking Cessation drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Smoking Cessation?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Smoking Cessation therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Smoking Cessation and their status?
- What are the key designations that have been granted to the emerging drugs?
- Achieve Life Sciences
- Embera Pharmaceuticals
- Camino Pharma
- NFL Biosciences
- Astraea
- Antidote Therapeutics
- Mydecine Innovations
- Cytisinicline
- EMB-001
- SBP 9330
- NFL-101
- AT-1001
- ATI-3009
- MYCO-001
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Smoking Cessation: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Smoking Cessation– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Cytisinicline: Achieve Life Sciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- EMB-001: Embera Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- SBP-9330: Camino Pharma, LLC
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Smoking Cessation Key Companies
- Smoking Cessation Key Products
- Smoking Cessation- Unmet Needs
- Smoking Cessation- Market Drivers and Barriers
- Smoking Cessation- Future Perspectives and Conclusion
- Smoking Cessation Analyst Views
- Smoking Cessation Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.